A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Trial ID # NCT03093155
Phase II
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Bevacizumab, Ixabepilone
Eligible Participant

Platinum resistant, refractory or persistent ovarian cancer; median 3 prior therapies; 18% Pt-Rf, 55% w/ prior Bev

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


ORR, PFS, OS, evaluated per RECIST


Bev+Ixa (n=39) vs Ixa (n=37):

ORR: 33 vs 8%, p=0.004
PFS: 5.5 vs 2.2 months, HR: 0.33 (0.19-0.55, p<0.001)
OS: 10.0 vs 6.0 months, HR: 0.52 (0.31-0.87, p=0.006)

Clinically Significant Adverse Events

Serious AE: 1 bowel perforation in Ixa+Bev arm
Grade 3-4 AE:


Bevacizumab+ixabepilone is a well-tolerated, effective combination for treatment of platinum/taxane resistant ovarian cancer that extends both PFS/OS relative to ixabepilone monotherapy and prior receipt of bevacizumab should not preclude use of ixabepilone+bevacizumab


Roque DM et al. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Br J Cancer (2022) 126(12):1695-1703

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.